Asset
TIPELUKAST
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05464784 | phase2 | active_not_recruiting | 2022-08-22 | 2026-12-31 | MediciNova | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia |
| NCT02681055 | phase2 | completed | 2016-03-01 | 2018-05-30 | MediciNova | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects |
| NCT00295854 | phase2 | completed | 2005-05-01 | 2006-10-01 | MediciNova | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis |
| NCT02503657 | phase2 | completed | 2016-03-09 | 2020-12-07 | MediciNova | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis |
FDA applications (0)
This company has no applications containing this asset.